HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IBA Connects Members With FDA Compliance Expert As MoCRA Deadlines Loom

Executive Summary

The Independent Beauty Association joins with Registrar Corp to provide IBA members with expert resources for preparing for deadlines under the Modernization of Cosmetics Regulation Act.

You may also be interested in...



Doc On Call? Cosmetic Manufacturers May Need M.D. On Retainer Under MoCRA

Cosmetic manufacturers may need to retain a medical professional to determine if adverse events they receive are minor or serious given the looming deadline for maintaining records and reporting serious adverse events to the US FDA, says Locke Lord partner David Abramowitz.

MoCRA Check-In: Postscript To My Three Minutes At US FDA's Cosmetics GMP ‘Listening Session’

EAS Consulting Group’s John Bailey is checking in with HBW Insight periodically in 2023 to offer his views on developments under the US Modernization of Cosmetic Regulations Act of 2022. Here he provides his experience with, and takeaways from, the US FDA’s 1 June virtual “listening session” on good manufacturing practices for cosmetic products.

FDA Will Be Motivated To Bring Enforcement Action Under MoCRA; ‘Get Your Ducks In a Row’

The US Food and Drug Administration will have new cosmetics requirements to enforce under the Modernization of Cosmetic Regulations Act, as well as new funds and pressure “to make a show of this,” Locke Lord attorneys said in the law firm’s 31 May “MoCRA and You” webinar.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel